In-Silico Drug Discovery Market Size, Share, Industry Analysis, Trends, Growth, 2032

In-Silico Drug Discovery Industry Prospective:

The global In-Silico drug discovery market size was worth around USD 2,942.7 million in 2023 and is predicted to grow to around USD 7,526.3 million by 2032 with a compound annual growth rate (CAGR) of roughly 11% between 2024 and 2032.       

Request Free Sample

In-Silico Drug Discovery Market: Overview

The process of finding and creating new medications through the use of computational methodologies and procedures is known as "in-silico drug discovery." It includes a vast array of computer programs, simulations, and algorithms designed to find possible drug candidates, forecast their characteristics, and maximize their safety and effectiveness. Because it takes less time and money to screen compounds experimentally, in-silico drug discovery speeds up the drug development process. On top of that, it makes it possible to identify new drug candidates that conventional approaches alone could have missed and to explore a wider chemical space.

Key Insights

• As per the analysis shared by our research analyst, the global In-Silico Drug Discovery market is estimated to grow annually at a CAGR of around 11% over the forecast period (2024-2032).
• In terms of revenue, the global In-Silico Drug Discovery market size was valued at around USD 2,942.7 million in 2023 and is projected to reach USD 7,526.3 million, by 2032.
• The growing technological advancement is expected to propel the market growth during the forecast period.
• Based on the product, the Software-as-a-Service is expected to grow at the highest CAGR during the forecast period.
• Based on the workflow, the Discovery segment is expected to grow at a significant rate over the forecast period.
• Based on the target therapeutic area, the Oncological disorders segment is expected to dominate the market during the forecast period.
• Based on the end user, the Pharmaceutical and Biopharmaceutical Companies segment is expected to capture the largest market share over the forecast period.
• Based on region, North America is expected to lead the market during the forecast period.

Request Free Sample

In-Silico Drug Discovery Market: Growth Drivers

Technological advancements drive market growth

Computational biology's quick technical developments are also driving the worldwide in-silico drug discovery market. Computational techniques have contributed to the discovery of novel medicinal compounds. Developments in computational biology have further streamlined the data processing and analysis stages of sequencing, leading to faster turnaround times and higher precision. These developments have led to an industry-wide need for better integrated storage and computing node utilization strategies. It is projected that this integration will lower the cost of data transport, remove bottlenecks in downstream processing, and improve communication within the computational analytics community. One popular computational method for finding hits in the early stages of drug development is virtual screening.

In-Silico Drug Discovery Market: Restraints

Limited time to analyze hinders market growth

The market for in-silico drug discovery is only constrained by its brief duration. This approach has analysis periods ranging from tens to hundreds of nanoseconds, and it is computationally demanding depending on the size of the stimulated systems. This is problematic because the time interval, which can be anywhere from milliseconds to seconds, is often too brief to detect protein folding. This may lead to an inadequate sampling of protein conformations as a result. Therefore, the short duration of analysis time might be a major restraining factor for the market growth over the forecast period.

In-Silico Drug Discovery Market: Opportunities

Growing clinical trials offer a lucrative opportunity for market growth

The increasing number of clinical trials drives the industry growth over the anticipated period. For instance, in June 2023, the world's first anti-fibrotic small molecule inhibitor to be found and designed using generative artificial intelligence (AI), INS018_055, has reached the first patient dose in the Phase II clinical trial, according to Insilico Medicine ("Insilico"), a clinical-stage biotechnology company. Now, phase II clinical trials will start to gather more data.

This 12-week oral INS018_055 dose will be tested for safety, tolerability, pharmacokinetics, and preliminary efficacy in four parallel cohorts of IPF patients as part of a randomized, double-blind, placebo-controlled study. To evaluate the candidate in bigger populations, the business plans to enrol 60 IPF patients at about 40 locations in the US and China.

In-Silico Drug Discovery Market: Challenges

The complexity of biological systems poses a major challenge to market expansion

Complex biological system modeling is still quite difficult, even with advances in computing techniques. Because they are so dynamic, biological systems frequently entail interactions between many proteins, pathways, and cellular functions. It is challenging and requires interdisciplinary knowledge in computational science, chemistry, and biology to create accurate models that adequately represent this complexity.

In-Silico Drug Discovery Market: Segmentation

The global In-Silico Drug Discovery industry is segmented based on Product, Workflow, Target Therapeutic Area, End User and region.

Based on the product, the global In-Silico Drug Discovery market is bifurcated into Software-as-a-Service, Software and Consultancy-as-a-Service. The Software-as-a-Service is expected to grow at the highest CAGR during the forecast period. The primary reason for this is that these solutions facilitate data mining, data analysis, and decision-making for users by offering features like decentralization and real-time data management. These solutions also help to cut down on the overall expense and time of the drug discovery process. Furthermore, their use for virtual screening and target fishing in the drug development process is growing.

Based on the workflow, the global In-Silico Drug Discovery industry is segmented into Pre-Clinical Tests, Discovery and Clinical Tests. The Discovery segment is expected to grow at a significant rate over the forecast period. An increasing number of biotech businesses are concentrating only on the in-silico development of new drugs. These businesses frequently use state-of-the-art computational methods, such as molecular dynamics simulations and machine learning, to discover new drug targets, create small molecules or biologics, and forecast the safety and efficacy of those products. Startups may also provide academic researchers or pharmaceutical businesses with in-silico screening services.

Based on the target therapeutic area, the global In-Silico Drug Discovery market is segmented into Metabolic disorders, HIV, Infectious diseases, Musculoskeletal disorders, Mental disorders, Neurological disorders and Oncological disorders. The Oncological disorders segment is expected to dominate the market during the forecast period. The segment expansion is attributed to the growing prevalence of cancer across the globe. According to the study by the National Institutes of Health, in India, the number of cancer cases will rise by 12.8% in 2025 compared to 2020.

Based on the end user, the global In-Silico Drug Discovery industry is segmented into Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies and Academic and Research Institutes. The Pharmaceutical and Biopharmaceutical Companies segment is expected to capture the largest market share over the forecast period. By eliminating the requirement for experimental screening and optimization of drug candidates, in-silico technologies let pharmaceutical companies streamline their drug development process and save time and money. This efficiency improvement allows companies to launch new treatments onto the market faster, potentially increasing revenue from product sales. Consequently, propelling market expansion.

In-Silico Drug Discovery Market: Report Scope

Regional Analysis

North America is expected to lead the market during the forecast period

North America is expected to lead the market growth during the forecast period. The regional market growth is attributed to the presence of major players such as Charles River Laboratories, Curia Global Inc. and others. These players investing in this technology to develop drugs faster. For instance, in September 2023, a multi-program collaboration agreement was announced by Related Sciences, a data science-driven drug discovery company, and Charles River Laboratories International, Inc. to deploy LogicaTM to numerous previously undrugged targets in the RS portfolio. Logica is a medication solution driven by artificial intelligence (AI) that converts biological information into optimal assets.

As part of the partnership, RS will collaborate closely with the Charles River and Valo Health teams to utilize Logica in the search for novel therapeutics that will address important unmet needs in a variety of disease categories, such as inflammatory disorders, cancer immunotherapy, and autoimmune. Additionally, the rising prevalence of various diseases such as cancer, mental, and infectious further boosts the industry growth in the region. For instance, the Centers for Disease Control and Prevention (CDC) released updated estimates for 2021 that show about 32,100 new cases of HIV infection in the US.

In-Silico Drug Discovery Market: Competitive Analysis

The global In-Silico Drug Discovery market is dominated by players like:

• Charles River Laboratories
• Curia Global Inc.
• Certara
• USA
• Chemical Computing Group ULC
• GenScript
• Sygnature Discovery
• Abzena Ltd.
• BioNTech SE
• Creative Biostructure

The Global In-Silico Drug Discovery market is segmented as follows:

By Product

• Software-as-a-Service
• Software
• Consultancy-as-a-Service

By Workflow

• Pre-Clinical Tests
• Discovery
• Clinical Tests

By Target Therapeutic Area

• Metabolic disorders
• HIV
• Infectious diseases
• Musculoskeletal disorders
• Mental disorders
• Neurological disorders
• Oncological disorders

By End User

• Contract Research Organizations
• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa